Pharmaceutical companies invest tens of billions of dollars annually into research and development (Fierce Biotech, Drug Discovery & Development). A firm will be considered an "AI-centered drug development startup" if it A) characterizes itself as a firm that primarily uses AI technologies in order to identify novel drug candidates, and B) was founded in the year 2019 or later. Whether the announced acquisition is completed is irrelevant, and the announcement of a joint venture will not count. In the event that two or more companies simultaneously (i.e., exact same date and time) announce a qualifying acquisition, the more highly ranked company in terms of 2024 research budget will be considered to have announced first. For the purposes of this question, a drug (including biologics) will be considered novel if it has never been approved for trial by a national (e.g., FDA) or supranational (e.g., EU's EMA) regulatory body in the past.

Confused? Check our FAQ or ask us for help. To learn more about Good Judgment and Superforecasting, click here.

To learn more about how you can become a Superforecaster, see here. For other posts from our Insights blog, click here.